# Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

> **NCT05446831** · PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 35 (estimated)

## Conditions studied

- ITP
- Immune Thrombocytopenia

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT05446831
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-13
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05446831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05446831, "Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05446831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*